Affinity Asset Advisors LLC Has $17.71 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Affinity Asset Advisors LLC raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 9.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 940,083 shares of the company’s stock after purchasing an additional 79,684 shares during the quarter. Nurix Therapeutics accounts for about 2.4% of Affinity Asset Advisors LLC’s holdings, making the stock its 14th biggest position. Affinity Asset Advisors LLC’s holdings in Nurix Therapeutics were worth $17,711,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. US Bancorp DE grew its position in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after purchasing an additional 842 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after acquiring an additional 877 shares during the period. ADAR1 Capital Management LLC bought a new stake in Nurix Therapeutics in the 4th quarter valued at about $207,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $209,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $266,000.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $9.85 on Tuesday. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The stock has a market capitalization of $750.92 million, a PE ratio of -3.41 and a beta of 2.23. The company’s 50 day simple moving average is $13.84 and its two-hundred day simple moving average is $19.06.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. During the same period in the previous year, the firm earned ($0.76) earnings per share. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Wall Street Analyst Weigh In

NRIX has been the subject of several analyst reports. Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. Leerink Partners began coverage on shares of Nurix Therapeutics in a report on Monday, March 17th. They set a “market perform” rating and a $16.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Needham & Company LLC cut their price objective on Nurix Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Finally, Stifel Nicolaus lowered their price objective on Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $30.44.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $488,660.76. This trade represents a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 in the last ninety days. 7.20% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.